Thrombosis |
-Thrombin Binding to Platelet Glycoprotein Ib
Is Influenced by the HPA-2 Polymorphism
From the Laboratory for Thrombosis Research, IRC, KULeuven Campus Kortrijk, Belgium and Institute for Clinical Immunology and Transfusion Medicine (H.K., S.S.), Justus Liebig University, Giessen, Germany.
Correspondence to Dr Hans Deckmyn, Laboratory for Thrombosis Research, IRC, KULeuven Campus Kortrijk, E. Sabbelaan 53, 8500 Kortrijk, Belgium. E-mail Hans.Deckmyn{at}kulak.ac.be
Objective Glycoprotein (GP) Ib
is the functionally dominant subunit of the platelet GPIb-IX-V receptor complex. The N-terminal domain of the GPIb
chain contains binding sites for
-thrombin and von Willebrand factor (VWF). The human platelet alloantigen (HPA)-2 polymorphism of the GPIb
gene is associated with a C/T transition at nucleotide 1018, resulting in a Thr/Met dimorphism at residue 145 of GPIb
. To study the structural and functional effects of this dimorphism, N-terminal fragments (AA1-289) of the HPA-2a and HPA-2b alloform of GPIb
expressed in CHO cells were used.
Methods and Results Of 74 moAbs directed against human GPIb
, 2 antibodies with epitope between AA1-59 could differentiate between both alloforms. In addition, VWF bound with a higher affinity to the recombinant HPA-2a fragment or to homozygous HPA-2a platelets. In contrast, no difference was found in the binding of
-thrombin to the recombinant alloform fragments or of antibodies directed against the
-thrombin binding anionic sulfated tyrosine sequence (AA269-282).
Conclusions Whereas the Thr145Met dimorphism does not affect
-thrombin binding, it does influence the conformation of the N-terminal flanking region and first leucine-rich repeat of GPIb
and by this has an effect on VWF binding.
Key Words: glycoprotein Ib Willebrand HPA-2 polymorphism thrombin
This article has been cited by other articles:
![]() |
J. P. Corsetti, D. Ryan, A. J. Moss, D. L. Rainwater, W. Zareba, and C. E. Sparks Glycoprotein Ib{alpha} Polymorphism T145M, Elevated Lipoprotein-Associated Phospholipase A2, and Hypertriglyceridemia Predict Risk for Recurrent Coronary Events in Diabetic Postinfarction Patients Diabetes, May 1, 2007; 56(5): 1429 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. De Meyer, K. Vanhoorelbeke, M. K. Chuah, I. Pareyn, V. Gillijns, R. P. Hebbel, D. Collen, H. Deckmyn, and T. VandenDriessche Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor Blood, June 15, 2006; 107(12): 4728 - 4736. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Vijayan and P. F. Bray Molecular Mechanisms of Prothrombotic Risk Due to Genetic Variations in Platelet Genes: Enhanced Outside-In Signaling Through the Pro33 Variant of Integrin {beta}3. Experimental Biology and Medicine, May 1, 2006; 231(5): 505 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ulrichts, M. Udvardy, P. J. Lenting, I. Pareyn, N. Vandeputte, K. Vanhoorelbeke, and H. Deckmyn Shielding of the A1 Domain by the D'D3 Domains of von Willebrand Factor Modulates Its Interaction with Platelet Glycoprotein Ib-IX-V J. Biol. Chem., February 24, 2006; 281(8): 4699 - 4707. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mikkelsson, M. Perola, and P. J. Karhunen Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 113 - 125. [Abstract] [PDF] |
||||
![]() |
J. A. Iniesta, R. Gonzalez-Conejero, C. Piqueras, V. Vicente, and J. Corral Platelet GP IIIa Polymorphism HPA-1 (PlA) Protects Against Subarachnoid Hemorrhage Stroke, October 1, 2004; 35(10): 2282 - 2286. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |